KMTS (Kestra Medical Technologies) Operating Income: $-143.61 Mil (TTM As of Jan. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

KMTS Kestra Medical Technologies Ltd KMTS
10 GF Score
Price $24.24
! 4 Warning Signs
View Full Analysis

What is Kestra Medical Technologies Operating Income?

Kestra Medical Technologies KMTS -2.34% 10 Operating Income is $-143.61 Mil as of Jan. 2026. GuruFocus rates KMTS with a GF Score™ of 10/100. The stock has 4 warning signs investors should review.

Kestra Medical Technologies's Operating Income for the three months ended in Jan. 2026 was $-34.77 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jan. 2026 was $-143.61 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Kestra Medical Technologies's Operating Income for the three months ended in Jan. 2026 was $-34.77 Mil. Kestra Medical Technologies's Revenue for the three months ended in Jan. 2026 was $24.55 Mil. Therefore, Kestra Medical Technologies's Operating Margin % for the quarter that ended in Jan. 2026 was -141.60%.

Kestra Medical Technologies's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Kestra Medical Technologies's annualized ROC % for the quarter that ended in Jan. 2026 was -205.75%. Kestra Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 was -245.40%.


Kestra Medical Technologies  (NAS:KMTS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Kestra Medical Technologies's annualized ROC % for the quarter that ended in Jan. 2026 is calculated as:

ROC % (Q: Jan. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Oct. 2025 ) + Invested Capital (Q: Jan. 2026 ))/ count )
=-139.06 * ( 1 - 0% )/( (59.647 + 75.527)/ 2 )
=-139.06/67.587
=-205.75 %

where

Invested Capital(Q: Oct. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=246.701 - 27.396 - ( 175.424 - max(0, 35.756 - 195.414+175.424))
=59.647

Invested Capital(Q: Jan. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=379.342 - 32.683 - ( 291.321 - max(0, 42.931 - 314.063+291.321))
=75.527

Note: The Operating Income data used here is four times the quarterly (Jan. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Kestra Medical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jan. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jan. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Oct. 2025  Q: Jan. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-128.972/( ( (47.892 + max(-15.713, 0)) + (57.218 + max(-20.179, 0)) )/ 2 )
=-128.972/( ( 47.892 + 57.218 )/ 2 )
=-128.972/52.555
=-245.40 %

where Working Capital is:

Working Capital(Q: Oct. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(10.413 + 6.918 + 2.659) - (27.396 + 0 + 8.307)
=-15.713

Working Capital(Q: Jan. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(12.709 + 6.829 + 3.204) - (32.683 + 0 + 10.238)
=-20.179

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jan. 2026) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Kestra Medical Technologies's Operating Margin % for the quarter that ended in Jan. 2026 is calculated as:

Operating Margin %=Operating Income (Q: Jan. 2026 )/Revenue (Q: Jan. 2026 )
=-34.765/24.552
=-141.60 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kestra Medical Technologies Operating Income Related Terms


Kestra Medical Technologies Operating Income Historical Data

* Premium members only.

The historical data trend for Kestra Medical Technologies's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kestra Medical Technologies Operating Income Chart

Kestra Medical Technologies Annual Data
Trend Apr20 Apr21 Apr23 Apr24
Operating Income
-29.32 -32.71 -80.42 -85.06

Kestra Medical Technologies Quarterly Data
Apr20 Jul20 Apr21 Jul21 Apr23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26
Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.60 -48.21 -28.88 -31.76 -34.77
KMTS
10GF Score
Kestra Medical Technologies Ltd KMTS
Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kestra Medical Technologies Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jan. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-143.61 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Income →
What does a Operating Income of $-143.61 Mil mean?
Kestra Medical Technologies (KMTS) has a Operating Income of $-143.61 Mil as of Jan. 2026. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Kestra Medical Technologies and its competitors.
Is Kestra Medical Technologies' Operating Income too high?
Kestra Medical Technologies' current Operating Income is $-143.61 Mil. Overall, Kestra Medical Technologies has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Kestra Medical Technologies' Operating Income compare to ATRC and STAA?
Kestra Medical Technologies' Operating Income of $-143.61 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Income for a Medical Devices & Instruments company?
A good Operating Income depends on the Medical Devices & Instruments industry context. However, Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Income mean?
A high Operating Income can signal that a stock is expensive relative to its fundamentals. Operating Income equals sales less all operating expenses. It is linked to EBIT. View historical data on Kestra Medical Technologies and its competitors. Kestra Medical Technologies's current Operating Income is $-143.61 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kestra Medical Technologies stock overvalued right now?
Kestra Medical Technologies (KMTS) has a current Operating Income of $-143.61 Mil. The current Operating Income is $-143.61 Mil. Kestra Medical Technologies' overall GF Score™ is 10/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Income calculated?
Operating Income is calculated from a company's financial statements. For Kestra Medical Technologies (KMTS), the current Operating Income is $-143.61 Mil as of Jan. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kestra Medical Technologies Business Description

Address 3933 Lake Washington Boulevard NE, Suite 200, Kirkland, WA, USA, 98033
Kestra Medical Technologies Ltd is a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. It has developed and is commercializing its Cardiac Recovery System platform, a comprehensive and developed system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of its Cardiac Recovery System platform is the ASSURE WCD, a next-generation wearable cardioverter defibrillator (WCD) used to protect patients at an elevated risk of sudden cardiac arrest (SCA), a prominent public health problem.
10GF Score

Get the complete analysis for KMTS

Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$24.24
Price